Inside Rocket Lab’s Paradox: Record Revenue, Insider Exodus, and the SpaceX Shadow

Four executives sold $18M in shares after a spring rally, bringing total insider sales to $67M. Despite record revenue and a Nasdaq-100 inclusion, the stock fell 10% on SpaceX's IPO day.

Four Rocket Lab executives cashed out roughly $18 million in shares after the stock’s spring rally, bringing total insider sales over the past three months to nearly $67 million. The selling spree adds an uncomfortable layer to a company that just posted record revenue, doubled its orders, and secured a spot in the Nasdaq-100.

The timing could hardly be worse. The stock closed at €88.70 on Friday, down more than 10% in a single session and roughly 34% below the May peak of €133.80. Insiders are trimming positions just as the broader market is rotating capital toward a freshly public SpaceX.

An IPO Gravity Well

SpaceX’s long-awaited debut sent shockwaves through the publicly traded space sector. Investors moved money into the Elon Musk-led giant, leaving rivals like Rocket Lab in the dust. Friday’s 10.6% drop was part of a broader sell-off that market observers attribute to a classic rotation — not a verdict on Rocket Lab’s underlying health.

The rotation overshadowed two significant catalysts. Nasdaq confirmed on June 11 that Rocket Lab will join the Nasdaq-100 index effective June 22, a move that typically triggers automatic buying from index funds. And Rocket Lab recently completed its 100th Electron rocket on the production line, a milestone reached less than nine years after its first commercial launch in May 2017. The company has set a target of 100 Electron launches in 2026, which would make it the fastest privately developed orbital rocket in history.

Neither achievement was enough to stop the slide on IPO day.

Fundamentals Tell a Different Story

First-quarter 2026 revenue hit a record $200.3 million, up 63.5% year over year. The order backlog swelled to $2.2 billion — more than double the level from a year earlier. Rocket Lab signed 31 launch contracts in the quarter alone, exceeding the total for all of 2025, and the manifest now stands at more than 70 missions extending into 2029.

Second-quarter guidance calls for revenue between $225 million and $240 million, suggesting the momentum is far from fading. Management has pointed to a record pace of production and a growing backlog of government and commercial customers.

CEO Peter Beck has highlighted the buildup of test stands for the upcoming Neutron rocket as the next major milestone. The first launch is targeted for the fourth quarter of 2026, after a tank incident in January pushed back the original timeline. A successful Neutron debut would put Rocket Lab in direct competition with SpaceX’s Falcon 9, opening a much larger addressable market for both government and commercial contracts.

Technicals and the Analyst View

The stock is trading just above its 50-day moving average of €87.42 — a level that technical traders are watching closely. A sustained break below that mark could invite additional selling pressure. On a longer timeframe, however, the picture remains robust: shares have gained roughly 36% year to date and nearly 290% over the past twelve months.

Of the 16 analysts covering the name, 14 rate it a buy and none recommend selling. The average price target stands at $105.28, implying meaningful upside even after the recent correction. The consensus view is that Rocket Lab’s operational trajectory remains intact and that the current weakness is a temporary consequence of the SpaceX liquidity event rather than a deterioration in fundamentals.

For now, the market is caught between a record order book and insider exits, between index inclusion and IPO rotation. The resolution may hinge on Neutron’s schedule and whether the broader space sector can absorb a new, much larger player without swallowing its smaller rivals whole.